An official website of the United States government
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
Trial Status: active
RBS2418 is a targeted immune modulator that inhibits ectonucleotide
pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor
immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine
monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and
promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4
inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The
hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly
immunogenic, and enhance anti-tumor responses in adult participants with advanced,
unresectable hepatocellular carcinoma (HCC) compared to STRIDE alone.
Inclusion Criteria
At least 18 years of age on the day of signing informed consent.
Male and female participants with advanced, unresectable HCC who are eligible to receive STRIDE regimen as first line therapy.
Willing to submit a pre-treatment tissue sample (archival or fresh tissue if archival is not available).
Exclusion Criteria
BCLC stage D disease at the time of screening or prior to first dose of RBS2418.
Child-Pugh class equal or higher than B8 at the time of screening or within 7 days prior to the first dose of study treatment.
Eligible for curative treatments (e.g., surgical resection, liver transplantation, or local ablation).
Evidence of rapid progression on prior therapy resulting in rapid clinical deterioration.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07175441.
